Recent Updates — SNN
Smith & Nephew plc announced an interim cash dividend of 15.6 US cents per ordinary share, payable on November 6, 2026, to shareholders of record as of October 2, 2026. UK residents and those who elected sterling payments will receive 11.65 pence per share. Smith & Nephew plc is a global medical technology company specializing in orthopaedic implants, sports medicine products, wound management, and ENT devices.
Smith & Nephew plc announced the redemption of the entire outstanding principal amount of its $350,000,000 5.150% Notes due 2027 on September 18, 2026. The securities will be redeemed on October 5, 2026, at a price calculated per the governing Indenture, causing interest to cease accruing and listing cancellation on the New York Stock Exchange shortly thereafter. This debt extinguishment reduces the company's leverage profile. Smith & Nephew plc operates in the medical technology industry, designing and manufacturing orthopaedic, sports medicine, ENT, and wound management products.
Smith+Nephew announced the results of its cash tender offer for up to $250 million of its outstanding 2.032% Senior Notes due 2030. The aggregate principal amount of notes validly tendered and not withdrawn was $431,825,000, exceeding the maximum tender amount and triggering a proration scaling factor of 57.995%. The company accepted $250,000,000 in principal amount at a consideration of U.S.$878.90 per U.S.$1,000 principal amount. Accepted notes will be canceled, and the settlement date is expected to be September 18, 2026. Smith+Nephew operates in the medical technology industry, focusing on the repair, regeneration, and replacement of soft and hard tissue through orthopaedics, sports medicine, and wound management products.
Smith+Nephew announced the pricing of a cash tender offer for up to $250 million of its outstanding 2.032% Senior Notes due 2030, which have an aggregate principal amount of $900 million outstanding. The company set the tender consideration at U.S.$878.90 per U.S.$1,000 principal amount, based on a fixed spread over the reference yield as of September 15, 2026. The offer expired on that date and is subject to proration if oversubscribed, with settlement expected on September 18, 2026. Smith+Nephew operates in the medical technology industry, focusing on the repair, regeneration, and replacement of soft and hard tissue through orthopaedics, sports medicine, and wound management products.